RxDoctor Payments Data

Thanh Nguyen, MD

Nephrology · Garden Grove, CANPI 1508885625

Payments from drug & device makers

$62,173in general payments, 2019–2025

Across 362 payments — averaging $171.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$19K
  • Boehringer Ingelheim$11K
  • Johnson & Johnson$10K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • Lilly USA, LLC$6K
  • AstraZeneca$3K
  • plus $8K from 36 others

What the payments were for

  • Consulting fees$5501%
  • Speaking & faculty fees$36,68359%
  • Travel & lodging$4,0186%
  • Food & beverage$20,81533%
  • Education$1070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,173 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$124,999
Medicare patients
174
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin468$380,545
KerendiaFinerenone227$213,454
TradjentaLinagliptin137$109,716
Evenity (2 Syringes)Romosozumab-Aqqg32$75,403
TrulicityDulaglutide63$69,698
ProliaDenosumab34$58,172
VascepaIcosapent Ethyl112$53,668
LinzessLinaclotide84$52,664
RybelsusSemaglutide43$50,398
MyrbetriqMirabegron48$45,054
OzempicSemaglutide29$41,015
JanuviaSitagliptin Phosphate60$40,762
FarxigaDapagliflozin Propanediol49$34,066
Dexlansoprazole DrDexlansoprazole136$29,038
TrintellixVortioxetine Hydrobromide32$23,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$11,287$507,456626 claims
BayerKerendia$469$213,454227 claims
AmgenEvenity (2 Syringes), Prolia, Aranesp$18,503$156,984102 claims
Novo NordiskRybelsus, Ozempic$466$91,41272 claims
Lilly USA, LLCTrulicity$5,525$69,69863 claims
AbbVieLinzess$416$52,66484 claims
MerckJanuvia$106$40,76260 claims
AstraZenecaFarxiga$2,678$34,06649 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$6,840$23,69532 claims
PfizerEliquis$125$11,05311 claims
GSKBreo Ellipta$142$7,91020 claims
Johnson & JohnsonXarelto$9,768$6,64212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →